Cerebrolysin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Cerebrolysin

Also known as: CBL, FPF-1070, Cere

Neuropeptide preparation / Neurotrophic agent — mixture of low-molecular-weight peptides and amino acids derived from porcine brain

Research chemicalLast updated: November 4, 2026Based on 38 peer-reviewed studies

What it is

Cerebrolysin is a neuropeptide preparation used in many countries for stroke recovery and Alzheimer's disease, though it is not approved in the USA. It's made from purified brain tissue and is thought to mimic protective growth signals in the nervous system. Approved in Europe and Asia for neurological conditions; not FDA-approved.

The scientific side

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. Its mechanism of action is described as resembling the activity of endogenous neurotrophic factors. Key reported mechanisms include: induction of neurogenesis, neuroplasticity, neuroprotection, and neurotrophicity; modulation of endogenous neurotrophic factor expression including BDNF, GDNF, NGF, CNTF, VEGF, IGF-1, and TNF-α (PMID 37052231, 22229324; IGF-1: PMID 19531281); stabilization of the blood-brain barrier by reducing pro-inflammatory and pro-coagulation proteins (ICAM-1, HMGB1, TNF-α, phosphorylated NF-κB-p65) and increasing tight junction proteins (ZO-1, occludin, claudin) in vitro; and protection of the neurovascular unit. The preparation contains neurotrophic factors including BDNF, GDNF, NGF, and CNTF among active peptide fragments. Its biological effects are described as similar to endogenous neurotrophic effects and it can cross the blood-brain barrier.

Class: Neuropeptide preparation / Neurotrophic agent — mixture of low-molecular-weight peptides and amino acids derived from porcine brain

Legal & regulatory status

US FDA

Not approved for use in the USA. Regulatory approval status in other jurisdictions not explicitly stated in reviewed literature — requires manual verification.

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.